Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422

Watchlist Manager
Sichuan Kelun Pharmaceutical Co Ltd Logo
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
Watchlist
Price: 30.5 CNY 0.63%
Market Cap: 48.8B CNY
Have any thoughts about
Sichuan Kelun Pharmaceutical Co Ltd?
Write Note

Sichuan Kelun Pharmaceutical Co Ltd
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sichuan Kelun Pharmaceutical Co Ltd
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
Non-Reccuring Items
ÂĄ1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Non-Reccuring Items
ÂĄ12.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Non-Reccuring Items
ÂĄ4.8m
CAGR 3-Years
-52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Non-Reccuring Items
ÂĄ778.9k
CAGR 3-Years
-46%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Non-Reccuring Items
ÂĄ3.7m
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Non-Reccuring Items
ÂĄ146.4k
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sichuan Kelun Pharmaceutical Co Ltd
Glance View

Market Cap
48.8B CNY
Industry
Pharmaceuticals

Nestled in the vibrant economic tapestry of China, Sichuan Kelun Pharmaceutical Co., Ltd. has emerged as a formidable player in the healthcare industry. Established in the late 1990s, the company embarked on its journey with a commitment to the development and production of intravenous infusion solutions. These infusion products have become the lifeblood of Kelun's operations, offering a critical healthcare solution that serves both domestic and international markets. By leveraging advanced technology and maintaining stringent quality control, Kelun ensures its offerings meet the diverse and demanding needs of modern medical practice. The company's narrative intertwines innovation with growth, as reflected in its expansive product range that has evolved to encompass antibiotics, traditional Chinese medicine, and comprehensive research in biotechnology. But Kelun's story doesn't stop there; it stands out in the pharmaceutical landscape through its integrated business model. By investing heavily in research and development, Kelun fuels its pipeline with new drugs, ensuring a steady stream of clinically effective and market-ready products. It also navigates strategic alliances and collaborations, stitching together a network that amplifies its market penetration and operational scalability. These moves not only consolidate its standing in the healthcare sector but also streamline supply chains, thereby optimizing revenues. With an agile approach that adapts to regulatory changes and market dynamics, Sichuan Kelun Pharmaceutical continues to script a narrative of resilience and business acumen in the global arena.

Intrinsic Value
44.05 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Sichuan Kelun Pharmaceutical Co Ltd's Non-Reccuring Items?
Non-Reccuring Items
1.6m CNY

Based on the financial report for Sep 30, 2024, Sichuan Kelun Pharmaceutical Co Ltd's Non-Reccuring Items amounts to 1.6m CNY.

What is Sichuan Kelun Pharmaceutical Co Ltd's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
-52%

Over the last year, the Non-Reccuring Items growth was -52%.

Back to Top